vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Iridium Communications Inc. (IRDM). Click either name above to swap in a different company.
Iridium Communications Inc. is the larger business by last-quarter revenue ($219.1M vs $139.2M, roughly 1.6× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 9.9%, a 25.6% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 1.9%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 4.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Iridium Communications Inc. is a publicly traded American company headquartered in McLean, Virginia, United States. Iridium operates the Iridium satellite constellation, a system of 80 satellites: 66 are active satellites and the remaining fourteen function as in-orbit spares. Iridium Satellites are used for worldwide voice and data communication from handheld satellite phones, satellite messenger communication devices and integrated transceivers, as well as for two-way satellite messaging se...
ADMA vs IRDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $219.1M |
| Net Profit | $49.4M | $21.6M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 23.2% |
| Net Margin | 35.5% | 9.9% |
| Revenue YoY | 18.4% | 1.9% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $219.1M | ||
| Q4 25 | $139.2M | $212.9M | ||
| Q3 25 | $134.2M | $226.9M | ||
| Q2 25 | $122.0M | $216.9M | ||
| Q1 25 | $114.8M | $214.9M | ||
| Q4 24 | $117.5M | $213.0M | ||
| Q3 24 | $119.8M | $212.8M | ||
| Q2 24 | $107.2M | $201.1M |
| Q1 26 | — | $21.6M | ||
| Q4 25 | $49.4M | $24.9M | ||
| Q3 25 | $36.4M | $37.1M | ||
| Q2 25 | $34.2M | $22.0M | ||
| Q1 25 | $26.9M | $30.4M | ||
| Q4 24 | $111.9M | $36.3M | ||
| Q3 24 | $35.9M | $24.4M | ||
| Q2 24 | $32.1M | $32.3M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | 23.2% | ||
| Q4 25 | 45.1% | 25.9% | ||
| Q3 25 | 38.0% | 30.9% | ||
| Q2 25 | 35.1% | 23.2% | ||
| Q1 25 | 30.4% | 28.1% | ||
| Q4 24 | 32.6% | 24.5% | ||
| Q3 24 | 33.1% | 25.8% | ||
| Q2 24 | 36.6% | 21.7% |
| Q1 26 | — | 9.9% | ||
| Q4 25 | 35.5% | 11.7% | ||
| Q3 25 | 27.1% | 16.4% | ||
| Q2 25 | 28.1% | 10.1% | ||
| Q1 25 | 23.4% | 14.2% | ||
| Q4 24 | 95.2% | 17.1% | ||
| Q3 24 | 30.0% | 11.5% | ||
| Q2 24 | 29.9% | 16.1% |
| Q1 26 | — | — | ||
| Q4 25 | $0.20 | $0.24 | ||
| Q3 25 | $0.15 | $0.35 | ||
| Q2 25 | $0.14 | $0.20 | ||
| Q1 25 | $0.11 | $0.27 | ||
| Q4 24 | $0.45 | $0.30 | ||
| Q3 24 | $0.15 | $0.21 | ||
| Q2 24 | $0.13 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | — |
| Total Assets | $624.2M | — |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $87.6M | $96.5M | ||
| Q3 25 | $61.4M | $88.5M | ||
| Q2 25 | $90.3M | $79.3M | ||
| Q1 25 | $71.6M | $50.9M | ||
| Q4 24 | $103.1M | $93.5M | ||
| Q3 24 | $86.7M | $159.6M | ||
| Q2 24 | $88.2M | $63.5M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | $1.8B | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $1.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $477.3M | $462.6M | ||
| Q3 25 | $431.2M | $450.5M | ||
| Q2 25 | $398.3M | $473.6M | ||
| Q1 25 | $373.4M | $518.4M | ||
| Q4 24 | $349.0M | $576.6M | ||
| Q3 24 | $231.9M | $663.8M | ||
| Q2 24 | $188.3M | $786.7M |
| Q1 26 | — | — | ||
| Q4 25 | $624.2M | $2.5B | ||
| Q3 25 | $568.7M | $2.6B | ||
| Q2 25 | $558.4M | $2.6B | ||
| Q1 25 | $510.6M | $2.6B | ||
| Q4 24 | $488.7M | $2.7B | ||
| Q3 24 | $390.6M | $2.8B | ||
| Q2 24 | $376.4M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | 3.80× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 3.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | 13.7% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $108.6M | ||
| Q3 25 | $13.3M | $100.8M | ||
| Q2 25 | $21.1M | $129.6M | ||
| Q1 25 | $-19.7M | $61.1M | ||
| Q4 24 | $50.2M | $104.8M | ||
| Q3 24 | $25.0M | $118.6M | ||
| Q2 24 | $45.6M | $81.1M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $75.1M | ||
| Q3 25 | $-1.1M | $79.2M | ||
| Q2 25 | $18.7M | $108.9M | ||
| Q1 25 | $-24.4M | $36.5M | ||
| Q4 24 | $47.5M | $80.5M | ||
| Q3 24 | $24.0M | $100.0M | ||
| Q2 24 | $43.6M | $68.7M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 35.3% | ||
| Q3 25 | -0.8% | 34.9% | ||
| Q2 25 | 15.3% | 50.2% | ||
| Q1 25 | -21.2% | 17.0% | ||
| Q4 24 | 40.4% | 37.8% | ||
| Q3 24 | 20.0% | 47.0% | ||
| Q2 24 | 40.7% | 34.2% |
| Q1 26 | — | 13.7% | ||
| Q4 25 | 0.8% | 15.7% | ||
| Q3 25 | 10.7% | 9.5% | ||
| Q2 25 | 2.0% | 9.5% | ||
| Q1 25 | 4.1% | 11.4% | ||
| Q4 24 | 2.3% | 11.4% | ||
| Q3 24 | 0.9% | 8.7% | ||
| Q2 24 | 1.9% | 6.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 4.37× | ||
| Q3 25 | 0.36× | 2.71× | ||
| Q2 25 | 0.62× | 5.90× | ||
| Q1 25 | -0.73× | 2.01× | ||
| Q4 24 | 0.45× | 2.88× | ||
| Q3 24 | 0.70× | 4.85× | ||
| Q2 24 | 1.42× | 2.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
IRDM
| Voice and data | $57.4M | 26% |
| IoT data (2) | $46.0M | 21% |
| Government | $39.5M | 18% |
| Government service revenue (5) | $27.6M | 13% |
| Subscriber equipment | $20.2M | 9% |
| Hosted payload and other data service (4) | $14.8M | 7% |
| Broadband (3) | $12.2M | 6% |
| Commercial | $1.3M | 1% |
